← Back to Screener
BriaCell Therapeutics Corp. Warrant (BCTXZ)
Price$0.08
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-92.18%
Price vs S&P 500 (4W)-16.10%
VGM Score23.37
All Metrics
Price vs S&P 500 (YTD)-84.27%
10-Day Avg Trading Volume0.08M
3-Month Avg Trading Volume0.05M
52-Week High$1.14
26-Week Price Return-80.79%
13-Week Price Return-45.15%
3-Month Return Std Dev177.94%
Year-to-Date Return-72.54%
5-Day Price Return-0.38%
Month-to-Date Return-0.38%
Price vs S&P 500 (13W)-55.65%
52-Week Low$0.06
mGradeD
vgmGradeD
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BCTXZBriaCell Therapeutics Corp. Warrant | — | — | D | $0.08 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
BriaCell Therapeutics is a clinical-stage biotechnology company developing targeted cell-based immunotherapies for cancer. Its lead program, Bria-IMT, is in late-stage clinical trials for breast cancer, while Bria-OTS is a personalized off-the-shelf immunotherapy platform targeting breast and prostate cancers. The company is pursuing combination therapy approaches through clinical collaborations to enhance treatment efficacy.